Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04717050 · ClinicalTrials.gov registry record · NA

Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity

A NA study of Breast Cancer and Stroke, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
NA
Development phase
160
Enrollment target
1
Study location

NCT04717050 is a NA study of Breast Cancer and Stroke that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 160 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04717050, a NA study of Breast Cancer and Stroke, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

This study is about testing whether exercise will improve fitness and lessen risk factors related to heart disease, diabetes, and obesity in Latina breast cancer survivors.

Interventions

  • BEHAVIORAL Progressive combine training (PCT)
  • BEHAVIORAL Attention Control (AC)

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2021-08-12
Est. Completion 2026-06-15
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT04717050

The ClinicalTrials.gov registry entry for NCT04717050 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Progressive combine training (PCT) is the first listed.

NCT04717050 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04717050 about?

NCT04717050 is a clinical study titled "Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity". This study is about testing whether exercise will improve fitness and lessen risk factors related to heart disease, diabetes, and obesity in Latina breast cancer survivors.

What is the current status of trial NCT04717050?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2021-08-12. Estimated completion is 2026-06-15.

What conditions does trial NCT04717050 study?

This clinical trial studies the following conditions: Breast Cancer, Stroke, Coronary Artery Disease, Type2 Diabetes.

What interventions are being tested in trial NCT04717050?

The interventions under investigation include: Progressive combine training (PCT) (BEHAVIORAL), Attention Control (AC) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04717050?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04717050 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.